Evolving trends in dupilumab use for chronic rhinosinusitis with nasal polyps (CRSwNP): a 4-year cohort analysis
Abstract Chronic rhinosinusitis with nasal polyps (CRSwNP) affects up to 4.5% of the population and is frequently driven by type 2 inflammation. Dupilumab, targeting IL‑4 and IL‑13 pathways, was approved in 2019 as the first biologic for CRSwNP in Germany. This single-center, retrospective study ana...
Zapisane w:
| Główni autorzy: | , , , , |
|---|---|
| Format: | Artigo |
| Język: | Inglês |
| Wydane: |
Nature Portfolio
2025-12-01
|
| Seria: | Scientific Reports |
| Hasła przedmiotowe: | |
| Dostęp online: | https://doi.org/10.1038/s41598-025-17787-4 |
| Etykiety: |
Nie ma etykietki, Dołącz pierwszą etykiete!
|